da Silva et identified factors that are predictive of adverse drug effects in a patient being treated with benznidazole for Chaga's disease (Trypanosoma cruzi). These can help to identify a patient who may benefit from closer management or who may have to discontinue therapy. The authors are from the Evandro Chagas National Institute of Infectious Diseases. Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.